Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

334
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
334
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

523
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
523
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HAC1 contributes to stress adaptation and virulence in the emerging fungal pathogen Candida auris.

Medical mycology·2026
Same author

Influence of hypoxic conditions on Trichosporon asahii virulence in a Galleria mellonella infection model.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2026
Same author

Clinical and Microbiological Insights Into Invasive Fusariosis Following Allogeneic Hematopoietic Stem Cell Transplantation: A 15-Year Single-Center Analysis.

Transplant infectious disease : an official journal of the Transplantation Society·2026
Same author

Comparative Evaluation of 3D-QALAS Myelin Volume Fraction, Inhomogeneous Magnetization Transfer, and Myelin Water Fraction.

AJNR. American journal of neuroradiology·2026
Same author

Post-radiofrequency ablation empyema-a staged multidisciplinary protocol for colonic and diaphragmatic perforation: a case report.

AME case reports·2026
Same author

A modified Cerfolio technique for robotic pulmonary resection: a retrospective comparison with the conventional approach.

General thoracic and cardiovascular surgery·2026

Related Experiment Video

Updated: Mar 12, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Multiple myeloma: progress in management aimed at improving QoL.

Masahiro Abe1

  • 1Tokushima University Graduate School, Department of Hematology, Endocrinology and Metabolism Medicine and Bioregulatory Sciences.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|November 1, 2016
PubMed
Summary

Despite advances in myeloma treatment, bone destruction significantly impacts patient quality of life (QoL). New anabolic therapies are needed to restore bone and prevent further destruction, improving long-term QoL.

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K

Related Experiment Videos

Last Updated: Mar 12, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K

Area of Science:

  • Oncology
  • Bone Metabolism
  • Hematology

Background:

  • Multiple myeloma frequently causes bone destruction, leading to poor quality of life (QoL).
  • Improved survival in myeloma necessitates better management of bone disease.
  • Current treatments focus on anti-resorptive agents, but bone restoration is lacking.

Purpose of the Study:

  • To discuss the long-term management of myeloma bone disease.
  • To explore novel treatment modalities for bone destruction in multiple myeloma.
  • To provide a perspective on developing new bone-modifying agents.

Main Methods:

  • Literature review of current and emerging myeloma therapies.
  • Analysis of bone anabolic and anti-resorptive mechanisms.
  • Discussion of clinical perspectives on bone disease management.

Main Results:

  • Bone destruction remains a major challenge in multiple myeloma despite new treatments.
  • Existing anti-resorptive agents manage but do not restore bone.
  • Novel anabolic agents are anticipated for bone restoration and prevention.

Conclusions:

  • Effective bone management is crucial for maintaining QoL in myeloma patients.
  • Future research should focus on bone-restoring anabolic therapies.
  • Integrated treatment strategies are needed for myeloma bone disease.